<DOC>
	<DOCNO>NCT01536743</DOCNO>
	<brief_summary>The purpose study obtain estimate biochemical response rate determine CA125 response use Gynecologic Cancer Intergroup ( GCIG ) response criterion PD0332991 patient recurrent ovarian epithelial carcinoma . CA125 response define ≥ 50 % decrease baseline CA125 level confirm ≥ 21 day initial evaluation ( baseline define high value 2 pre-treatment CA125 assessment ) .</brief_summary>
	<brief_title>A Open Label Study Efficacy Safety PD0332991 Selective Inhibitor Cyclin Dependent Kinases 4 6 Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency Low p16 Expression</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologicallyconfirmed ovarian epithelial ( include fallopian tube primary peritoneal ) carcinoma . 2 . 2 . Baseline paraffin embed tissue patient 's primary diagnosis request study enrolment forward designated central laboratory central assessment Rb p16 expression perform use immunohistochemistry . In patient measurable disease tissue biopsy may obtain core biopsy submit designated central laboratory . 3 . GCIGdefined CA125 progression absence disease upon image smallvolume asymptomatic disease upon image progress follow one , two three line chemotherapy recurrent disease . 4 . If patient smallvolume disease current study restrict patient minimal ascites cause abdominal distention/mesenteric thicken require paracentesis , lesion ≤4 cm spiral compute tomography [ CT ] magnetic resonance image [ MRI ] baseline . 5 . Two pretreatment CA125 value ( document two occasion take least one week apart ) must least twice upper limit normal , twice nadir value pretreatment CA125 value never normalize . 6 . Patients platinumsensitive platinumresistant disease define recurrence progression disease &gt; 6 month ≤ 6 month completion frontline platinum base chemotherapy . 7 . ECOG performance status ≤ 1 patient ≥21 year age . 8 . Resolution toxic effect prior therapy ( except alopecia ) NCI CTCAE v.3.0 Grade ≤ 1 baseline laboratory value define inclusion criterion immediately . 9 . Adequate organ bone marrow function evidence : hemoglobin ≥ 9.0 g/dL absolute neutrophil count ≥ 1.5 x 109/L platelet count ≥ 100 x 109/L Renal function , follow : Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ≥ 40 mL/min AST ALT ≤ 2.5 x ULN total bilirubin ≤ 1.5 x ULN unless increase due Gilbert 's disease similar syndrome involve slow conjugation bilirubin , 10 . Adequate coagulation parameter ( within 21 day prior registration ) , International Normalized Ratio ( INR ) ≤1.5 ; Activated ProThrombin Time ( APTT ) ≤ 1.5 x ULN . 11 . Patient must willing able comply schedule visit , treatment plan , laboratory test , study procedure . 12 . Informed consent must obtain write patient prior perform study/screening procedure prior registration study . Exclusion Criteria Patients present follow include study : 1 . More 4 prior chemotherapy regimens treatment ovarian cancer . 2 . Anticipation immediate need major surgical procedure ( e.g. , impend bowel obstruction , gastrointestinal perforation ) radiation therapy trial . 3 . Diagnosis second malignancy within last 5 year , except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uteri breast . 4 . Treatment chemotherapy , radiotherapy , surgery , blood product , investigational agent within 3 week trial enrolment . 5 . Any follow within 6 month prior trial registration : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis , thromboembolic event . PD0332991 Recurrent Ovarian Cancer 6 . History brain metastasis , spinal cord compression , carcinomatous meningitis . 7 . Patient childbearing potential evidently pregnant ( eg , positive human chorionic gonadotropin test ) breast feeding . A woman child bear potential define surgically sterile postmenopausal le 6 month . 8 . Patient childbearing potential willing use adequate contraceptive precaution . Adequate effective method contraception result low failure rate , le 1 % per year , nonhormonal IUD , condom , sexual abstinence vasectomise partner . 9 . Known active infection , antiretroviral therapy HIV disease positive test chronic hepatitis B C infection . 10 . Mental condition render patient unable understand nature , scope , possible consequence trial . 11 . Refusal inability give inform consent participate trial . 12 . Corrected QT ( QTc ) interval &gt; 470 msec . 13 . If radiotherapy require give patient , patient withdrawn study . 14 . Current use anticipate need : Food drug know strong CYP3A4 inhibitor ( i.e . grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , posaconazole , erythromycin , clarithromycin , telithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , nefazodone , diltiazem , delavirdine . 15 . Other severe acute chronic medical psychiatric condition , significant laboratory abnormality require investigation may cause undue risk patient 's safety , inhibit protocol participation , interfere interpretation trial result , judgment investigator would make patient inappropriate entry trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>